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standards laid down in the 1964 Declaration of 
Helsinki and its later amendments. Owing to 
the retrospective design of the planned stud‑
ies, no additional patient consent is required.
Statistical analysis The statistical tests will be 
selected individually for each analysis to com‑
pare the population and long ‑term outcomes 
from a  given RCT to the  population from 
the registries.
Results and discussion Below we present 
a practical systematic approach based on an an‑
alytical model taking into consideration the set‑
ting of RCT and daily clinical practice. The ana‑
lytical model presents the principles underlying 
an attempt to translate evidence from an RCT 
of a new drug or procedure (RCT ‑X) to the re‑
al‑world setting of patients with a given dis‑
ease. The main objective of the analytical mod‑
el is to determine the target population and as‑
sess the potential impact of a new drug or pro‑
cedure on improving the patient’s prognosis. 
Additionally, in selected subgroups, the model 
will assess whether patients treated by differ‑
ent drugs or methods in daily clinical practice 
derive similar benefits to those shown by RCTs.
The design of the analytical model is present‑
ed in FIGURE 1. The necessary methodological con‑
ditions and subsequent stages of the model are 
listed below:
1	 Study patients should be enrolled based on strict 
inclusion and exclusion criteria for the RCT ‑X.
Introduction Scientific societies stress the 
need for obtaining evidence from observational 
studies reflecting daily clinical practice.1 There‑
fore, it seems important to search for obser‑
vational analytical models based on dedicated 
methods and tools that would allow a combina‑
tion of experimental (randomized controlled tri‑
als [RCTs]) and observational (databases) find‑
ings. In this report, we propose a model that 
uses large registries of healthcare system data 
to investigate the potential impact of different 
RCT interventions on the outcomes of patients 
in everyday clinical practice.
Methods Characteristics of databases To 
meet the study objective, a large clinical data‑
base should be available that contains detailed 
information on clinical characteristics, thera‑
peutic procedures, pharmacologic therapy, and 
the incidence of adverse cardiovascular events 
in a long ‑term follow ‑up.
In the  planned real ‑world evaluation of 
RCTs, data from the following databases will 
be used: SILCARD (Silesian Cardiovascular Da‑
tabase),2 TERCET (Therapy in Tertiary Cardio‑
logical Center),3 PRESAGE (Prospective Regis‑
try of Stable Angina Management and Treat‑
ment),4 COMMIT ‑HF (Contemporary Modalities 
In Treatment of Heart Failure),5 Zabrze ‑ACS Reg‑
istry,6 Ochojec Angioplasty Registry, and Zabrze 
Cardiac Surgery Registry.
The study was approved by institutional re‑
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Extraction of patients with the disease entity
Do patients meet the inclusion criteria for the RCT-X trial?
Do patients meet the exclusion criteria for the RCT-X trial?
RCT-X–excluded
Patients who meet 
the exclusion criteria 
for the randomized trial
RCT-X–nonincluded
Patients who do not meet 
the inclusion criteria 
for the randomized trial




• Diagnostic and therapeutic procedures
• Pharmacotherapy
• Detailed data on the occurrence of adverse events during in-hospital and post-discharge follow-up




of the RCT-X–like group 
with the RCT-X–nonincluded 
and RCT-X–excluded groups
Comparative analysis of groups
treated with methods 1 and 2
COMPARATIVE ANALYSIS OF DRUG/METHODS 
IN RCT-X TRIAL IN SPECIFIC POPULATIONS 
OF PATIENTS




of the study / control group of the RCT-X 
trial with the RCT-X–like group
Are early- / long-term outcomes 
comparable?
Are early- / long-term outcomes 
comparable?
Are early- / long-term outcomes comparable?
Percentage of patients meeting the RCT-X 
criteria
Additional information in the context 
of evidence-based policy
Additional information in the context 
of evidence-based policy
Can the potential use of a drug / method 
of RCT-X trial aff ect real-world outcomes?
Generate new research hypotheses
Generate new research hypotheses
Causes of diff erences in early- / long-term outcomes
Study / control groups 





Meeting the criteria for the RCT-X trial
RCT-X–excluded
Treatment 
by drug / method 1
Treatment 
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4	 assessment of patients who do not meet 
the inclusion criteria and who meet the exclu‑
sion criteria in comparison with the selected 
study group.
The specific nature of RCTs requires that in‑
clusion criteria are precisely defined, which au‑
tomatically excludes part of the population with 
a given disease or undergoing a given proce‑
dure.7,8 Similarly, strict exclusion criteria are 
justifiable, considering patient safety, especially 
when implementing new therapies. This usual‑
ly results in the lack of good representativeness 
of the population enrolled in RCTs.9
The presented analytical model provides 
the basis for a series of comprehensive analy‑
ses that will allow a verification of scientific ev‑
idence from RCTs and guidelines in real ‑world 
populations. In addition to assessing the im‑
plementation of guidelines in everyday clini‑
cal practice, the outcomes of the analyses may 
also result in the generation of new hypotheses.
The analytical model is the next step in con‑
necting evidence ‑based medicine with evidence‑
‑based policy. A methodological analysis using 
large databases is extremely important from 
the perspective of the real ‑world population. 
The analysis should primarily focus on treatment 
strategies that cannot be tested in an RCT for eth‑
ical or financial reasons but also when the results 
of RCTs are inconclusive and when there is a high 
suspicion that the population, practice, or other 
factors in a given treatment strategy differ from 
those applied in the RCT.
We are aware that the  presented analyti‑
cal model has some limitations. In addition to 
the typical advantages associated with the reg‑
istry design of the study, the main limitation is 
potential selection bias, even after using multi‑
variable analysis and propensity score matching.
The availability of scientific evidence from 
RCTs has started a new era in medicine. It is dif‑
ficult to imagine modern medicine without scien‑
tific evidence from clinical trials. Without reliable 
RCTs and meta ‑analyses, progress seems virtual‑
ly impossible. Therefore, an increasing number of 
therapies are tested in RCTs. On the other hand, 
the assessment and verification of scientific ev‑
idence in the real ‑world population become not 
only a necessity but also a duty.10 In the context 
of the country’s healthcare policy, large observa‑
tional studies will allow a more favorable adjust‑
ment of cost valuations and access to health ser‑
vices for patients. Therefore, the presented ana‑
lytical model could facilitate verification of sci‑
entific evidence in the real ‑world setting.
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2	 Furthermore, the percentage ratio of selected 
patients to the initial study group should be de‑
termined. These patients will constitute the po‑
tential population in which a new drug or pro‑
cedure might be applied.
3	 Baseline characteristics, management, and 
treatment of the study group should be compared 
with those of the control group in the RCT ‑X. 
The results will show whether the selected pop‑
ulation is clinically similar to the population 
of the RCT ‑X. This condition has to be fulfilled 
at this stage in order to draw proper conclusions 
from further analysis.
4	 In the case of imbalance in baseline charac‑
teristics, a propensity score–matching analy‑
sis should be performed to balance analyzed 
groups (a sufficiently large study group of pa‑
tients is required).
5	 Subsequently, the frequency of adverse events 
during follow ‑up (primary and secondary end‑
points of the  RTC ‑X) should be determined 
and compared with that of the control group 
of the RCT ‑X. This analysis will show whether 
the study group has similar, better, or worse prog‑
nosis. Based on the obtained results, it will be possi‑
ble to determine whether the potential use of a giv‑
en drug or procedure tested in the RCT ‑X affects 
the treatment outcomes of the study population.
6	 If the results are different, we should always 
search for the possible reasons (regardless of 
the direction of the difference). Considering that 
the baseline characteristics of the groups are sim‑
ilar (or similar when balanced), this problem may 
be due to the quality of treatment, healthcare af‑
ter hospital discharge, patient compliance, and 
others. Identifying the reasons for these differ‑
ences may be a key to legitimizing the introduc‑
tion of a new drug or procedure into the health‑
care system.
7	 The next stage of the analytical model should 
be a comparative analysis of patients who do not 
meet the inclusion criteria and who meet the ex‑
clusion criteria in relation to the study group. 
This is valuable information that complements 
the analysis and can provide additional value 
for evidence ‑based policy.
8	 The summary should contain the analysis of 
evidence obtained from a large clinical database 
with economic assessment as well as its use for 
evidence ‑based policy purposes with the partic‑
ipation of leading experts.
The conclusions should include:
1	 precise determination of the percentage of pa‑
tients in the study population who meet the in‑
clusion and exclusion criteria for the RCT ‑X;
2	 comparison with other similar analyses and 
identification of potential differences in rela‑
tion to the selected population;
3	 determination of whether the study group 
has comparable baseline characteristics, imple‑
mented treatment, and prognosis in relation to 
the results of the RCT ‑X;
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